Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124723742 | 12472374 | 2 | F | 2016 | 20160711 | 20160616 | 20160719 | PER | US-ELI_LILLY_AND_COMPANY-US201606002247 | ELI LILLY AND CO | 76.00 | YR | M | Y | 0.00000 | 20160719 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124723742 | 12472374 | 1 | PS | CIALIS | TADALAFIL | 1 | Oral | 5 MG, QD | 21368 | 5 | MG | TABLET | QD | ||||||
| 124723742 | 12472374 | 2 | SS | CIALIS | TADALAFIL | 1 | 21368 | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124723742 | 12472374 | 1 | Erectile dysfunction |
| 124723742 | 12472374 | 2 | Benign prostatic hyperplasia |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124723742 | 12472374 | Drug ineffective | |
| 124723742 | 12472374 | Ejaculation disorder | |
| 124723742 | 12472374 | Erectile dysfunction | |
| 124723742 | 12472374 | Prostatic specific antigen increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124723742 | 12472374 | 1 | 20150424 | 0 |